Hormone-sensitive metastatic prostate cancer : docetaxel Evidence summary

    Randomised controlled trial (RCT) data suggest that docetaxel improves overall survival and time to disease progression in men with hormone-sensitive metastatic prostate cancer. Two RCTs found that, compared with androgen deprivation therapy (ADT) alone, docetaxel combined with ADT statistically significantly improved overall survival by around 10–15 months… CONTINUE READING